Who owns Enochian Biosciences Inc?
- Ticker: RENB
- CUSIP Number: 29350e104
Tip: Access positions for across all investors
Analyze quarterly positions in Enochian Biosciences with up to 7 years of data, all consolidated into one spreadsheet
Download as csv Download as ExcelTop investors of Enochian Biosciences stock
Who bought or sold Enochian Biosciences Inc this quarter?
Fund or Company Name | Shares Held | Valued At | Change in Shares | As Of | Actions |
---|---|---|---|---|---|
Vanguard Group | 3.9M | $10M | 904% | Mar 2024 |
|
Geode Capital Management | 438k | $1.2M | 44% | Mar 2024 |
|
Morgan Stanley | 375k | $995k | 181% | Mar 2024 |
|
BlackRock | 314k | $833k | 11% | Mar 2024 |
|
Goldman Sachs Group | 306k | $811k | 2279% | Mar 2024 |
|
Millennium Management | 294k | $778k | 132% | Mar 2024 |
|
Susquehanna International | 207k | $548k | 162% | Mar 2024 |
|
Citigroup | 188k | $500k | 268% | Mar 2024 |
|
Jane Street | 134k | $355k | 136% | Mar 2024 |
|
Jpmorgan Chase & Co | 120k | $319k | 304% | Mar 2024 |
|
Man Group | 108k | $286k | 100% | Mar 2024 |
|
Commonwealth Equity Services | 102k | $269k | 100% | Mar 2024 |
|
Northern Trust | 86k | $228k | 44% | Mar 2024 |
|
Laurion Capital Management | 62k | $163k | 0% | Mar 2024 |
|
ExodusPoint Capital Management | 59k | $156k | 100% | Mar 2024 |
|
Qube Research & Technologies | 44k | $116k | 393% | Mar 2024 |
|
Y-Intercept | 42k | $112k | 100% | Mar 2024 |
|
Balyasny Asset Management | 39k | $104k | 53% | Mar 2024 |
|
Toroso Investments | 37k | $98k | 100% | Mar 2024 |
|
Dimensional Fund Advisors | 36k | $96k | 0% | Mar 2024 |
|
Marshall Wace | 34k | $91k | 100% | Mar 2024 |
|
Brevan Howard Capital Management | 33k | $87k | 100% | Mar 2024 |
|
Leucadia National Corporation | 32k | $85k | 94% | Mar 2024 |
|
MSA Advisors | 25k | $79k | 100% | Dec 2023 |
|
CTC Alternative Strategies | 21k | $57k | 100% | Mar 2024 |
|
Cubist Systematic Strategies | 20k | $53k | 100% | Mar 2024 |
|
SG Americas Securities | 17k | $46k | 100% | Mar 2024 |
|
William Blair $ Company | 16k | $43k | 0% | Mar 2024 |
|
Hsbc Holdings | 15k | $49k | 100% | Dec 2023 |
|
Squarepoint Ops | 15k | $39k | 100% | Mar 2024 |
|
Victory Capital Management | 13k | $36k | 100% | Mar 2024 |
|
Polymer Capital Management | 12k | $31k | 100% | Mar 2024 |
|
Royal Bank of Canada | 5.4k | $14k | 100% | Mar 2024 |
|
Lazard Asset Management | 3.9k | $0 | 100% | Dec 2023 |
|
Point72 Asia | 1.9k | $4.9k | 100% | Mar 2024 |
|
UBS Group | 1.8k | $4.9k | -77% | Mar 2024 |
|
Bank of America Corporation | 1.8k | $4.7k | -96% | Mar 2024 |
|
Bnp Paribas Arbitrage, Snc | 1.2k | $3.1k | -3% | Mar 2024 |
|
Wells Fargo & Company | 294.00 | $779.011800 | 2% | Mar 2024 |
|
Who sold out of Enochian Biosciences?
Fund or Company Name | Date Sold | Shares Held | Valued At |
---|---|---|---|
683 Capital Management | Dec 2023 | 74k | $234k |
Citadel Advisors | Dec 2023 | 37k | $118k |
Virtu Financial | Dec 2023 | 19k | $59k |
Hrt Financial | Dec 2023 | 14k | $45k |
Schonfeld Strategic Advisors | Dec 2023 | 13k | $43k |
Bank of New York Mellon | Dec 2023 | 11k | $34k |